Back to news overview

Medux expands its position in healthcare | NPM Capital

News
Date
July 11, 2012
Medux expands its position in healthcare | NPM Capital

Medux B.V., onderdeel van investeringsmaatschappij NPM Capital, verwerft een meerderheidsbelang (65%) in twee vennootschappen van Ciran Revalidatie, te weten Top-Care Health Services en PRB-services. Ciran Revalidatie is gespecialiseerd in de poliklinische revalidatie van mensen met chronische fysieke klachten.

Participation in these companies is consistent with Medux’ strategy of sustainable value creation for all of the stakeholders involved in the provision of preventive and curative healthcare.

The acquisition will not affect the care provided for patients, the medical specialist ultimately responsible, or the personnel employed by the rehabilitation institute.

Ciran Revalidatie
Ciran specialises in the provision of rehabilitation services for patients with chronic physical ailments, who also suffer from psychological and social problems. The ailments are related to fatigue, pain and the postural and locomotor control systems. Treatment is designed to promote patient health, increase autonomy and enable full participation in society. Interventions are carried out by a team of specialised therapists under the responsibility of medical rehabilitation consultants.

Ciran’s mission is:
• To promote health in place of illness and autonomy in place of the need for care.
• To help improve the quality and affordability of (rehabilitation) care in the Netherlands with financing being based on the results achieved by treatment.

Ciran operates in partnership with nine Centres of Expertise with a total of twenty health care facilities in the Netherlands.

Medux
Care for wellbeing – in the broadest sense. This is what Medux stands for. With its brand-name companies, Harting-Bank, Emcart, Ligtvoet and Vitalis, Medux has established a strong position in the market for medical (rehabilitation) devices. With its investment in Ciran Medux has expanded its portfolio and taken a significant step in enabling the continued growth of a group of companies and activities that contribute to the delivery of better and more affordable healthcare in the Netherlands.

The acquisition will be finalised once all of the formalities have been completed and all of the approvals have been obtained, including the approval of the Netherlands Competition Authority (NMa). The acquisition is expected to be completed by 1 August 2012

NPM - Sfeer - 173 - clara tafel

Join our newsletter to stay informed of the most relevant updates